Elisabeth Ståhl
Research Subjects
Elisabeth Ståhl has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Bo Lundbäck
The OLIN Studies, Department of Medicine, Sunderby Central Hospital of Norrbotten, SE-971 80 Luleå, Sweden
2 shared publications - Fredrik Andersson
Health Economics & Outcomes Research, AstraZeneca R&D, Lund, Sweden
2 shared publications Klas Svensson
2 shared publications- Klas Svensson
AstraZeneca R&D, Lund, Sweden
2 shared publications Ad Schreurs
1 shared publication- Ann-Christin Jonsson
The OLIN Study Group, Sunderby Central Hospital of Norrbotten, Luleå, Sweden
1 shared publication
Latest Publications
- Open Access
- 7 April 2006
- Published by Springer Nature in Respiratory Research
- Vol. 7 (1) , 62
Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire
Background: Patient-reported outcomes (PRO) questionnaires are being increasingly used in COPD clinical studies. The challenge facing investigators is to determine what change is significant, ie what is the minimal clinically important difference (MCID). This study aimed to identify the MCID for the clinical COPD questionnaire (CCQ) in terms of patient referencing, criterion referencing, and by the standard error of measurement (SEM). Methods: Patients were ≥40 years of age, diagnosed with COPD, had a smoking history of >10 pack-years, and were participating in a randomized, controlled clinical trial comparing intravenous and oral prednisolone in patients admitted with an acute exacerbation of COPD. The CCQ was completed on Days 1–7 and 42. A Global Rating of Change (GRC) assessment was taken to establish the MCID by patient referencing. For criterion referencing, health events during a period of 1 year after Day 42 were included in this analysis. Results: 210 patients were recruited, 168 completed the CCQ questionnaire on Day42. The MCID of the CCQ total score, as indicated by patient referencing in terms of the GRC, was 0.44. The MCID of the CCQ in terms of criterion referencing for the major outcomes was 0.39, and calculation of the SEM resulted in a value of 0.21. Conclusion: This investigation, which is the first to determine the MCID of a PRO questionnaire via more than one approach, indicates that the MCID of the CCQ total score is 0.4.
- 7 April 2006
- Published by Springer Nature in Respiratory Research
- Vol. 7 (1) , 62
Open AccessHealth status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire
Background: Patient-reported outcomes (PRO) questionnaires are being increasingly used in COPD clinical studies. The challenge facing investigators is to determine what change is significant, ie what is the minimal clinically important difference (MCID). This study aimed to identify the MCID for the clinical COPD questionnaire (CCQ) in terms of patient referencing, criterion referencing, and by the standard error of measurement (SEM). Methods: Patients were ≥40 years of age, diagnosed with COPD, had a smoking history of >10 pack-years, and were participating in a randomized, controlled clinical trial comparing intravenous and oral prednisolone in patients admitted with an acute exacerbation of COPD. The CCQ was completed on Days 1–7 and 42. A Global Rating of Change (GRC) assessment was taken to establish the MCID by patient referencing. For criterion referencing, health events during a period of 1 year after Day 42 were included in this analysis. Results: 210 patients were recruited, 168 completed the CCQ questionnaire on Day42. The MCID of the CCQ total score, as indicated by patient referencing in terms of the GRC, was 0.44. The MCID of the CCQ in terms of criterion referencing for the major outcomes was 0.39, and calculation of the SEM resulted in a value of 0.21. Conclusion: This investigation, which is the first to determine the MCID of a PRO questionnaire via more than one approach, indicates that the MCID of the CCQ total score is 0.4.
- Open Access
- 16 September 2005
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 3 (1) , 1-58
Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older
Background: The age limit for some adult asthma clinical trials has recently been lowered to 12 years. In this study we have made minor modifications to the standardised version of the adult Asthma Quality of Life Questionnaire (AQLQ(S)) to make it valid for patients 12 years and older (AQLQ12+).Methods: We have used two clinical trial databases, in which the AQLQ12+ was used, to compare the measurement properties of the questionnaire in patients 12–17 years and patients 18 years and older. A total of 2433 patients (12–75 years), with current asthma and with data that could be evaluated both at randomisation and end of treatment, were included.Results: The analysis showed that internal consistency, responsiveness and correlations with other clinical indices were very similar in patients 12–17 years and patients 18 years and older.Conclusion: The measurement properties of the AQLQ12+ are similar in adolescents and adults and therefore the instrument is valid for use in adult studies which include children 12 years and older.
- 16 September 2005
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 3 (1) , 1-58
Open AccessModification of the asthma quality of life questionnaire (standardised) for patients 12 years and older
Background: The age limit for some adult asthma clinical trials has recently been lowered to 12 years. In this study we have made minor modifications to the standardised version of the adult Asthma Quality of Life Questionnaire (AQLQ(S)) to make it valid for patients 12 years and older (AQLQ12+).Methods: We have used two clinical trial databases, in which the AQLQ12+ was used, to compare the measurement properties of the questionnaire in patients 12–17 years and patients 18 years and older. A total of 2433 patients (12–75 years), with current asthma and with data that could be evaluated both at randomisation and end of treatment, were included.Results: The analysis showed that internal consistency, responsiveness and correlations with other clinical indices were very similar in patients 12–17 years and patients 18 years and older.Conclusion: The measurement properties of the AQLQ12+ are similar in adolescents and adults and therefore the instrument is valid for use in adult studies which include children 12 years and older.
- Open Access
- 9 September 2005
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 3 (1) , 1-56
Health-related quality of life is related to COPD disease severity
Background: The aim of this study was to evaluate the association between health-related quality of life (HRQL) and disease severity using lung function measures. Methods: A survey was performed in subjects with COPD in Sweden. 168 subjects (70 women, mean age 64.3 years) completed the generic HRQL questionnaire, the Short Form 36 (SF-36), the disease-specific HRQL questionnaire; the St George's Respiratory Questionnaire (SGRQ), and the utility measure, the EQ-5D. The subjects were divided into four severity groups according to FEV1 per cent of predicted normal using two clinical guidelines: GOLD and BTS. Age, gender, smoking status and socio-economic group were regarded as confounders. Results: The COPD severity grades affected the SGRQ Total scores, varying from 25 to 53 (GOLD p = 0.0005) and from 25 to 45 (BTS p = 0.0023). The scores for SF-36 Physical were significantly associated with COPD severity (GOLD p = 0.0059, BTS p = 0.032). No significant association were noticed for the SF-36, Mental Component Summary scores and COPD severity. Scores for EQ-5D VAS varied from 73 to 37 (GOLD I-IV p = 0.0001) and from 73 to 50 (BTS 0-III p = 0.0007). The SGRQ Total score was significant between age groups (p = 0.0047). No significant differences in HRQL with regard to gender, smoking status or socio-economic group were noticed. Conclusion: The results show that HRQL in COPD deteriorates with disease severity and with age. These data show a relationship between HRQL and disease severity obtained by lung function.
- 9 September 2005
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 3 (1) , 1-56
Open AccessHealth-related quality of life is related to COPD disease severity
Background: The aim of this study was to evaluate the association between health-related quality of life (HRQL) and disease severity using lung function measures. Methods: A survey was performed in subjects with COPD in Sweden. 168 subjects (70 women, mean age 64.3 years) completed the generic HRQL questionnaire, the Short Form 36 (SF-36), the disease-specific HRQL questionnaire; the St George's Respiratory Questionnaire (SGRQ), and the utility measure, the EQ-5D. The subjects were divided into four severity groups according to FEV1 per cent of predicted normal using two clinical guidelines: GOLD and BTS. Age, gender, smoking status and socio-economic group were regarded as confounders. Results: The COPD severity grades affected the SGRQ Total scores, varying from 25 to 53 (GOLD p = 0.0005) and from 25 to 45 (BTS p = 0.0023). The scores for SF-36 Physical were significantly associated with COPD severity (GOLD p = 0.0059, BTS p = 0.032). No significant association were noticed for the SF-36, Mental Component Summary scores and COPD severity. Scores for EQ-5D VAS varied from 73 to 37 (GOLD I-IV p = 0.0001) and from 73 to 50 (BTS 0-III p = 0.0007). The SGRQ Total score was significant between age groups (p = 0.0047). No significant differences in HRQL with regard to gender, smoking status or socio-economic group were noticed. Conclusion: The results show that HRQL in COPD deteriorates with disease severity and with age. These data show a relationship between HRQL and disease severity obtained by lung function.
- 1 September 2003
- Published by Elsevier in Respiratory Medicine
- Vol. 97 (9) , 1061-1066
Formoterol used as needed improves health-related quality of life in asthmatic patients uncontrolled with inhaled corticosteroids
- 1 September 2003
- Published by Elsevier in Respiratory Medicine
- Vol. 97 (9) , 1061-1066
Formoterol used as needed improves health-related quality of life in asthmatic patients uncontrolled with inhaled corticosteroids
- Open Access
- 1 January 2003
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 1 (1) , 1-18
Health-related quality of life, utility, and productivity outcomes instruments: ease of completion by subjects with COPD
An important outcome of any clinical intervention is the change in the subject's own perceived state of health. This can be categorized as health-related quality of life (HRQL), utility (preference-based health state), and daily life performance. 174 Swedish subjects with chronic obstructive pulmonary disease (COPD) (mean age 64.3 ± 12 years) completed five self-administered questionnaires: Short Form 36 (SF-36), St George's Respiratory Questionnaire (SGRQ), EuroQol-5D (EQ-5D), Health States-COPD (HS-COPD), and Work Productivity and Activity Impairment Questionnaire for COPD (WPAI-COPD). The subjects scored these outcomes instruments for ease of completion using a 5-point scale. The time taken to complete them was noted and the administrators' opinion of the subjects' comprehension of the questionnaires recorded using a 4-point scale.
- 1 January 2003
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 1 (1) , 1-18
Open AccessHealth-related quality of life, utility, and productivity outcomes instruments: ease of completion by subjects with COPD
An important outcome of any clinical intervention is the change in the subject's own perceived state of health. This can be categorized as health-related quality of life (HRQL), utility (preference-based health state), and daily life performance. 174 Swedish subjects with chronic obstructive pulmonary disease (COPD) (mean age 64.3 ± 12 years) completed five self-administered questionnaires: Short Form 36 (SF-36), St George's Respiratory Questionnaire (SGRQ), EuroQol-5D (EQ-5D), Health States-COPD (HS-COPD), and Work Productivity and Activity Impairment Questionnaire for COPD (WPAI-COPD). The subjects scored these outcomes instruments for ease of completion using a 5-point scale. The time taken to complete them was noted and the administrators' opinion of the subjects' comprehension of the questionnaires recorded using a 4-point scale.
- 1 August 2000
- Published by Elsevier in Respiratory Medicine
- Vol. 94 (8) , 735-741
Correlation between objective measures of airway calibre and clinical symptoms in asthma: a systematic review of clinical studies
- 1 August 2000
- Published by Elsevier in Respiratory Medicine
- Vol. 94 (8) , 735-741
Correlation between objective measures of airway calibre and clinical symptoms in asthma: a systematic review of clinical studies
- 1 April 2000
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 84 (4) , 397-402
Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis
- 1 April 2000
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 84 (4) , 397-402
Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis
- 1 January 1999
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 2 (1-4) , 117-122
Bambuterol is a more cost-effective treatment strategy than salmeterol in asthmatic patients with nocturnal symptoms
We aimed to compare the cost-effectiveness of oral bambuterol (Bambec®) 20 mg once daily with that of salmeterol (Serevent®) via pressurised metered dose inhaler (pMDI) 50 µg twice daily for treatment of asthma patients with nocturnal symptoms. One hundred and twenty six patients aged 18-70 years and using inhaled corticosteroids at a constant daily dose and with forced expiratory volume in one second (FEV1) 40-85% of predicted normal value, were included in this double-blind, randomised, parallel-group study (two weeks' run-in, six weeks' treatment) in the United Kingdom, Italy and Norway. During run-in, they had to have a nocturnal awakening or early awakening due to asthma symptoms that required rescue medication at least once during a two-week run-in period, and a > 15% fall in overnight peak expiratory flow (PEF) on at least three out of the last seven days. Morning and evening PEF were measured and tremor was scored. The effectiveness variables in the cost-minimisation analysis were symptom-free days and number of nights with no awakenings. Costs for both study and rescue medication were calculated. There were no statistically significant differences between bambuterol and salmeterol regarding morning and evening PEF (change from baseline), tremor, and the effectiveness variables. Mean number of symptom-free days was 25% vs. 20% and mean number of nights with no awakenings was 69% vs. 77% in the bambuterol and salmeterol groups, respectively. However treatment costs (study plus rescue medication) were lower during bambuterol treatment in all three countries. The per patient cost savings would be 47% in the UK, 27% in Italy and 40% in Norway if a patient changes from salmeterol to bambuterol. The conclusion is that the once-daily treatment with bambuterol is more cost-effective than the twice-daily treatment with salmeterol in asthma patients with nocturnal symptoms.
- 1 January 1999
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 2 (1-4) , 117-122
Bambuterol is a more cost-effective treatment strategy than salmeterol in asthmatic patients with nocturnal symptoms
We aimed to compare the cost-effectiveness of oral bambuterol (Bambec®) 20 mg once daily with that of salmeterol (Serevent®) via pressurised metered dose inhaler (pMDI) 50 µg twice daily for treatment of asthma patients with nocturnal symptoms. One hundred and twenty six patients aged 18-70 years and using inhaled corticosteroids at a constant daily dose and with forced expiratory volume in one second (FEV1) 40-85% of predicted normal value, were included in this double-blind, randomised, parallel-group study (two weeks' run-in, six weeks' treatment) in the United Kingdom, Italy and Norway. During run-in, they had to have a nocturnal awakening or early awakening due to asthma symptoms that required rescue medication at least once during a two-week run-in period, and a > 15% fall in overnight peak expiratory flow (PEF) on at least three out of the last seven days. Morning and evening PEF were measured and tremor was scored. The effectiveness variables in the cost-minimisation analysis were symptom-free days and number of nights with no awakenings. Costs for both study and rescue medication were calculated. There were no statistically significant differences between bambuterol and salmeterol regarding morning and evening PEF (change from baseline), tremor, and the effectiveness variables. Mean number of symptom-free days was 25% vs. 20% and mean number of nights with no awakenings was 69% vs. 77% in the bambuterol and salmeterol groups, respectively. However treatment costs (study plus rescue medication) were lower during bambuterol treatment in all three countries. The per patient cost savings would be 47% in the UK, 27% in Italy and 40% in Norway if a patient changes from salmeterol to bambuterol. The conclusion is that the once-daily treatment with bambuterol is more cost-effective than the twice-daily treatment with salmeterol in asthma patients with nocturnal symptoms.